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Summary: Using two new immunoradiometric assays for thyrotropin, we measured thyrotropin levels in
serum of patients suffering from various clinically and biochemically diagnosed thyroid disorders, and in
healthy controls. A thyroliberin Stimulation test was performed in all patients and controls. Thyrotropin
levels were measured using a solid phase IRMA in 339 patients and a coated tube sandwich assay in 152
patients. The lower limits of detection of 0.1 mU/1 (solid phase IRMA) and 0.02 mU/1 (coated tube sandwich
assay) äs well äs the specificity of these two assays were superior to those of conventional thyrotropin assays.
Basal thyrotropin values were clearly different between euthyroid controls and patients non responding to
thyroliberin Stimulation. However, the values for these two groups overlapped those for patients showing a
subnormal increase upon Stimulation with thyroliberin. The thyroliberin Stimulation test in patients with
autonomous adenomas, together with the measurement of thyrotropin using these sensitive assays, provides
additional Information in the low ränge below 1.0 mU/1, i. e. below the lower limit of detection of conventional
double antibody radioimmunoassays.
Vorteile von empfindlichen Assays für Thyrotropin in der Diagnostik von Schilddrüsenerkrankungen
Zusammenfassung: Thyrotropin-Konzentrationen im Serum von Patienten mit verschiedenen Schilddrüsener-
krankungen, die klinisch und laborchemisch vollständig abgeklärt waren sowie von Schilddrüsen-gesunden
Probanden wurden mit zwei neuentwickelten immunoradiometrischen Assays für Thyrotropin bestimmt. Ein
Thyroliberin (TRH)-Test wurde bei allen Patienten durchgeführt, bei 339 Patienten wurde Thyrotropin mit
einem solid phase IRMA bestimmt und bei 152 Patienten mit einem coated tube sandwich Assay. Die untere
Nachweisgrenze mit 0,1 mU/1 (solid phase IRMA) und mit 0,02 mU/1 (coated tube sandwich assay) war
ebenso wie die Spezifität der beiden Assays den herkömmlichen Thyrotropin-Assays überlegen. Es gelang
eine vollständige Unterscheidung zwischen euthyreoten Probanden und Patienten, die keinen Anstieg des
Thyrotropin auf Thyroliberin zeigten unter alleiniger Berücksichtigung der basalen Thyrotropin-Werte. In
beiden Assays gab es jedoch einen „Grenzbereich", in dem der Anstieg des Thyrotropin nach Gabe von
Thyroliberin nicht vorausgesagt werden konnte. Bei Probanden mit autonomen Adenomen erhält man mit
der Durchführung eines Thyroliberin-Tests und der Messung von Thyrotropin mit diesen empfindlichen
Assays eine zusätzliche Information im niedrigen Meßbereich unter 1.0 mU/1, das bedeutet in einem Bereich,
der unterhalb der unteren Nachweisgrenze von herkömmlichen Doppelantikörper-Radioimmunoassays liegt.
Introduction Recently, new assay methods for thyrotropin based
Within the last few years thyrotropin radioimmuno- on the IRMA technique and the use of monoclonal
assays using polyclonal antibodies have become suffi- antibodies have been introduced. Major advantages
ciently sensitive for the detection of thyrotropin levels of these newly developed methods are higher sensitiv-
i lower than the normal serum ränge. This increase in ity and shorter incubation periods, compared with
assay serisitivity, however, involved the use of cum- conventional double antibody radioimmunoassays.
bersome pröcedures for tracer purification, and pro- These assays permitted the Separation of healthy con-
longed incubation periods (1—4). trols and patients with overt hyperthyroidism using
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basal thyrotropin levels alone (5-10). However, the
diagnosis of hyperthyroidism is usually established
by measuring increased thyroid hormone levels, and
evaluation of thyrotropin secretion is not necessary.
For the diagnosis of borderline hyperthyroidism with
ambiguous peripheral thyroid hormone levels the per-
formance of a thyroliberin Stimulation test was also
necessary. The new thyrotropin assays would be an
advantage, if all non-responders to thyroliberin ad-
ministration could be separated from euthyroid per-
sons using basal thyrotropin levels alone. The Stimu-
lation test with thyroliberin would then no longer be
required.
In the present study thyroliberin tests were performed
in patients with various clinically and biochemicälly
diagnosed thyroid disorders, and in healthy controls.
Thyrotropin levels were determined using two new
sensitive assays with monoclonal antibodies.
Materials and Methods
New thyrotropin assays using monoclonal antibodies
Solidphase IRMA (Serono Diagnostics): Three different mono-
clonal antibodies raised against thyrotropin (TSH) were used.
Two antibodies labeled with 1251 are reportedly directed against
difierent epitopes both on the a- and ß-subunit of thyrotropin.
A third fluorescein isothiocyanate conjugated antibody detects
an epitope only present on the ß-subunit of thyrotropin. Stan-
dard or serum samples are incubated with these three antibodies
for 2 hours. The incubation period is terminated by adding a
sheep polyclonal antifluorescein isothiocyanate antibody
tagged to a magnetic solid phase. Separation of thyrotropin
antibody complex and free antibodies is achieved by exposure
to a magnetic field.
Coated tube sandwich assay (RIA gnost, hTSH, Behring): This
assay is performed in polystyrene tubes coated with a mono-
clonal antibody against the ß-subunit of thyrotropin. Standard
or serum samples are added together with a second monoclonal
antibody reacting with a determinant at the combining site of
a- and ß-subunits. This antibody is labeled with 125I. After
incubation the supernatant is decanted, then after washing the
tubes are placed into a gamma counter to determine wall-
bound radioactivity. This assay, now commercially available,
was kindly supplied by Behring for clinical evaluation.
Incubation procedures for both assays are detailed in table 1.
The coated tube sandwich assay was performed according to
the producer's instructions. For easier handiing we prolonged
the first incubation period of the solid phase IRMA overnight;
to reduce costs, only half of the original ,volumes was used.
Thyroliberin Stimulation test
In all patients a thyroliberin Stimulation test was performed:
serum levels of basal thyrotropin and thyrotropin 30 min after
injection of 200 g thyroliberin were determined. Thyrotropin
levels were measured using a solid phase IRMA from Öctober
to November 84 and using a coated tube sandwich assay in
December 84. In parallel, a conventional double antibody ra-
dioimmunoassay was used (11). This assay had a lower limit
of detection of 1.0 mU/1 and an incubation period of 48 hours.
Other methods
In addition, thyrpxine (T4), triiodothyronine (T3), thyroxine
binding globulin (TBG) were measured in all samples in a
conventional double antibody fadioimmunoassay (12, 13).
Patients
Diagnoses of patients included in the present study were based
on clinical and biochemical Parameters; in the case of autono-
mous adenoma diagnosis was achieved by technetium scan.
The various thyroid disorders of patients studied are given in
table 2. T4/TBG ratio and total T3 were within the normal
ränge in alj patients except in those suffering from overt hyper-
thyroidism.
To evaluate the diagnostic validity of basal thyrotropin alone,
the following groups were formed according to responsiveness
to thyroliberin:
first group:
no response to thyroliberin (TSH 30 min <0.5 mU/1 meas·-
ured with the solid phase IRMA, <0.1 mU/i with the coated
tube sandwich assay). This grbup comprises patients with
overt hyperthyroidism (elevated thyroid hormone levels) and
patients with borderline hyperthyroidism (normal T4/TBG
ratio and T3 levels). Patients with borderline hyperthyroidism
were suffering from autonomous adenomas, or thyrotoxicosis
after beginning drug therapy, or they were under treatment
with thyroid hprmones.
Tab. l. Incubation procedures of thyrotropin solid phase IRMA and coated tube sandwich assay. Modification of the solid
phase IRMA is presented in parenthesis.
Solid phase IRMA Coated tube sandwich assay
Standard, mU/1
Standard, serum,
125I thyrotropin antibody,
Incubate, h
0, (0.15), 0.4, 1.0, 5, 10, 30, 50
(WHO 80/558)
200 (100)
100 (50)
2 (16)
100 antibody to fluorescein isothiocyanate
— 10 min
magnetic Separation
decant
wash twice with 500 ml buffer
decant
count
0,0.15,0.5, 1.5,5, 15,50,
(WHO 80/558)
200
100
2
wash twice with l ml buffer
decant
count
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second group:
subnormal response to thyroliberin (TSH 30 min <3.0 mU/1
for both assays). Diagnoses see table 2.
third group:
normal response to thyroliberin (TSH 30 min 3.1 — 20 mU/1
for both assays).
This group comprises patients without thyroid disorders and
those with endernic goiter, defined äs euthyroidism in table
2.
Tab. 2. Numbers of patients with different thyroid disorders
according to thyrotropin response to thyroliberin ad-
ministration.
(1) no response, (2) subnormal response, (3) normal
response.
Euthyroidism
Thyroid horrnone
treatment of
endemic goiter
thyroid carcinomas
Autonomous adenomas
Hyperthyroidism (treated)
Hyperthyroidism (non treated)
Total
Solid
phase
IRMA
(3) j 215
(D 2
(2) t
,,|X .B*
(2) 1
(D 1(2) i
G
(1)
(2)
V)
"53
J5 26
% 18
o g
o 2
5 14
*o 5
5?
t 12
7
(1) -L 32
339
Coated
tube
sand-
wich
assay
79
7
20
6
4
7
5
2
7
15
152
Results
Assay characteristics
The lower limits of detection, based on results for
the zero Standard samples, plus 3 SD, were 0.1 mU/1
(solid phase IRMA) and 0.02 mU/1 (coated tube
sandwich assay). The intra- and interassay coefficient
of Variation for both assays are listed in table 3.
Cross reactivity
In order to evahiate the cross reactivity of the coated
tube sandwich assay with chorion gonadotropin, sera
from 66 pregnant women without thyroid disorders
were investigated. No difference in thyrotropin levels
was seen between women in the first trimenon and
those in the second or third trimenon. The mean
values of thyrotropin were 1.07 ± 1.03 mU/1
(x ± SD, n = 12) within the first trimenon, 1.06 ±
0.7 mU/1 (x ± SD, n = 31) in the second trimenon
and 1.19 ± 0.6 mU/1 (x ± SD, n = 23) in the third
trimenon.
Validity of the assays
In figure l basal thyrotropin levels measured with
the coated tube sandwich assay are plotted versus the
30 min values after thyroliberin administration; the
resulting correlation coefficient is 0.79 (n = 115).
Non-responders to thyroliberin were excluded from
Tab. 3. Assay characteristics of solid phase IRMA and coated tube sandwich assay.
Solid phase IRMA Coated tube sandwich assay
Lower limit of detection, mU/1
Intraassay Variation coefficient, n = 10
Interassay Variation coefficient, n = 10
0.1
34.5% (thyrotropin <0.1)
12.5% (thyrotropin = 0.27)
5.3% (thyrotropin = 0.73)
5.8% (thyrotropin = 1.89)
0.02
23% (thyrotropin = 0.35)
5.9% (thyrotropin = 0.79)
1.9% (thyrotropin = 2.11)
3.7% (thyrotropin = 3.96)
Tab. 4. Mean and ränge of thyrotropin concentration in sera
of normal, subnormal and non responding patients.
Euthyroidism
mean* mU/1
ränge, mU/1
Subnormal responders
mean, mU/1
ränge, mU/1
Hyperthyroidism
ränge, mU/1
Solid phase
IRMA
1.18 (n = 215)
0.4-2.5
0.38 (n = 32)
0.2-0.6
^0.2
Coated tube
sandwich
assay
1.14 (n =
0.3-2.3
0.22 (n =
0.03-0.9
£0.02
79)
36)
this calculation. The correlation coefficient from 247
thyroliberin tests with the solid phase IRMA was
0.71 (data not shown).
Figure 2 (solid phase IRMA) and figure 3 (coated
tube sandwich assay) show basal thyrotropin values
grouped according to the thyrotropin response to
thyroliberin without consideration of thyroid dis-
orders. Patients were divided into those with normal
and elevated thyroid hormone levels or according to
their thyrotropin response after thyroliberin respec-
tively (diagnoses see tab. 2). Mean values and ranges
are listed in table 4.
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Fig. 1. Solid phase IRMA. Concentrations of basal thyrotropin
measured in (left to right) patients unresponsive to
thyroliberin Stimulation and in those with subnormal
and normal responsiveness.
o TSH 30min ^0.5 mU/1, T4/TBG ratio and T3 elevated
α TSH 30 min ^0.5 mU/1, T4/TBG ratio and T3 normal
Δ TSH 30 min 0.6-1.0 mU/1
Δ TSH 30 min 1.1-2.0 mU/1
D TSH 30 min 2.1 -3.0 mU/1
o TSH 30 min ^3.1 mU/1
Fig. 3. Coated tube sandwich assay. Comparison of basal thy^·
rotropin values with those after Stimulation with thyro^
liberin.
2.5
2.0
o 15
(Λσ
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0.2
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Fig. 2. Coated tube sandwich assay. Text see figure 1.
o TSH 30 min ^  0.1 mU/1, T4/TBG ratio and T3 elevated
α TSH 30 min ^0.1 mU/1, T4/TBG ratio and T3 normal
A TSH 30 min 0.2-1.0 mU/1
Δ TSH 30 min 1.1-2.0 mU/1
D TSH 30 min 2.1-3.0 mU/1
O TSH 30min >3.1 mU/1
Solid phase IRMA (flg. 2)
Basal thyrotropin levels alone showed a clear dis-
crimination between e thyroid patients and those
non responding to thyroliberin. Patients with basal
thyrotropin values below the lower limit of detection
did not resppnd to thyroliberin (n = 78). In the group
of non-responders 32 patients were suffering from
overt hyperthyroidism, but 60 patients had normal
peripheral thyroid hormone,.leyels (borderline hyper-
thyroidism). The thyrotropin response to thyroliberin
could not be predicted in patients with basal thyrotro-
pin levels ranging from 0.2 to 0.7 mU/1. Thus, patients
with thyrotropin-levels of 0.2 and 0.3 m /1 showed
no increase (n = 14) or a subnormal response (n =
17) to thyroliberin. Patients with thyrotropin levels
from 0.4 up to 0.7 m /1 showed a subnormal inerease
(n = 15), but more frequently a normal increase upon
Stimulation with thyroliberin (n ^  59).
Coated tube sandwich assay (fig. 3)
Again, the basal thyrotropin levels alone discrimi-
nated between e thyroid patients and non-responders
to thyroliberin. Serum thyrotropin levels of 34 of 37
patients non responding to thyroliberin were below
the lower limit of detection of 0.02 ni /1; this group
comprises all hyperthyroid patients (n = 15). The
thyrotropin response to thyroliberin could not be
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predicted in patients with basal thyrotropin levels
ranging from 0.03 to 0.9 mU/1. Two of 7 patients
with basal values of 0.03 mU/1 showed no response,
and 5 could be stimulated up to 1.0 mU/1. Eleven
patients with thyrotropin levels from 0.3 to 0.9 mU/1
showed a subnormal increase, but again more fre-
quently a normal increase was seen (n = 38). The
individual thyroliberin test of patients with thyrotro-
pin levels below 0.06 mU/1 are shown in figure 4.
Euthyroid autonomous adenomas were detected in
Tc-scan. Patients with basal thyrotropin values below
0.02 mU/1 and no increase in thyrotropin after thyro-
liberin showed no paranodular uptake of nuclide
(n = 4). In those patients with basal thyrotropin in
the r nge of 0.03 and 0.06 mU/1 and a subnormal
increase in thyrotropin after thyroliberin administra-
tion, the nuclide was found not only in an adenoma,
but also in paranodular thyroid tissue.
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Fig. 4. Coated tube sandwich assay. Comparison of basal thy-
rotropin values in the r nge of ^  0.02 and 0.06 mU/1 with
those after Stimulation with thyroliberin.
Basal and thyrotropin 30 min are below the lower limit
of detection measured with a conventional radioim-
munoassay.
o hyperthyroidism, T4/TBG ratio and T3 elevated
DB autonomous adenoraa, normal T4/TBG ratio and
T3 levels
o thyrotoxicosis, after beginning drug therapy, nor-
mal thyroid hormone levels
Δ thyroid hormone therapy because of endemic goiter
or after remov l of the thyroid gland.
Basal thyrotropin values are plotted versus the 30 min
val e aftef thyroliberin administration and measured
with the coated tube sandwich
 β assay. All hyperthy-
roid patients are below 0.02 mU/1 (n = 15). All other
patients, i. e. those with normal pefipheral thyroid
hormone levels are below and above 0.02 mU/1 s
expected. These patients were suffering from the fol-
lowing thyroid disorders: endemic goitef during thy-
roid hormone therapy, thyroid carcinoma aftef re-
moval of the thyroid gland during thyroid drug thera-
py and thyrotoxicosis after beginning drug therapy.
Discussion
In the present study we have demonstrated that a
basal thyrotropin value, when determined in highly
sensitive assays provides Information on thyroid
function almost equivalent to that gained from meas-
urement of basal thyrotropin and thyrotropin 30 min
after injection of thyroliberin. This is shown in figure
l where the correlation coefficient between basal and
30 min thyrotropin is 0.79.
Moreover, work, cost and time can be saved in lab-
oratories, out patient clinics and wards by using only
basal thyrotropin levels for evaluating thyroid func-
tion. Furthermore, the well-known, but usually harm-
less side effects of thyroliberin injection are avoided.
Both assay Systems used in our study employ mono-
clonal antibodies against the -subunit of thyrotro-
pin. The inherent advantages of the monoclonal anti-
body approach are high specificity and sensitivity,
compared with conventional double antibody radio-
immunoassays. Cross reactivity with human
choriongonadotropin and gonadotropins, already ex-
cluded theoretically by the design of assay, was not
observed when thyrotropin levels were assessed dur-
ing the course of pregnancy in 66 women.
The use of the IRMA technique allows short incuba-
tion periods and provides a high- sensitivity. Even
with extremely prolonged incubation periods and
sophisticated purification of tracer (1—4), matrix
effects prevent the achievment of an equivalent per-
formance by conventional assays. Especially, when
measuring low levels of thyrotropin, the new assays
displayed a high precision. In contrast, conventional
assays show Variation coefficients up to 80% for low
thyrotropin values (14). Both the solid phase IRMA
and the coated tube sandwich assay yielded similar
values for the intraassay Variation coefficient, which
was 5 to 6% with a serum of 0.7 mU/1. The interassay
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Variation coefficients were also comparable with va-
lues of 3.7% and 5.8% with sera of 3.9 and 1.9 mU/1
respectively. Assay handling is more convenient for
the coated tube assay äs only one pipetting step is
required and Separation is easier.
The validity of both assays is similar in spite of the
limit of detection of 0.02 mU/1 for the coated tube
Sandwich assay compared with 0.1 mU/1 for the solid
phase IRMA. Both assays allow a clearcut discrimi-
nation of overt and borderline hyperthyroid patients
and euthyroid controls. Normal ranges for both as-
says were similar with 0.4 to 2.5 mU/1 for the solid
phase IRMA and with 0.3 to 2.3 mU/1 for the coated
tube sandwich assay.
An additional advantage of a sensitive thyrotropin
assay is shown in figure 4. Basal and 30 min values
were measured with the coated tube sandwich assay.
The highest 30 min value was 1.0 mU/1. All these
thyrotropin values were below the lower limit of
detection when measured with a conventional double
antibody radioimmunoassay. With the coated tube
sandwich assay basal thyrotropin values of all hyper-
thyroid patients were below the lower limit of detec-
tion of 0.02 mU/1. However, all other patients with
various thyroid disorders during drug therapy were
also either below 0.02 mU/1 or within the ränge of
0.03 to 0.06 mU/1. This is not surprising because
one would expect different degrees of thyrotropin
suppression depending on the duration of the thyro-
toxicosis and drug therapy. In one patient treated
with thyroid hormones after removal of the thyroid
gland because of carcinoma the basal thyrotropin
level was 0.06 niU/1 and showed no response after
thyroliberin administration. For this exception no
explanation yet is available.
The performance of a thyroliberin Stimulation test in
patients with autonomous adenomas may provide
additional Information on thyroj^J function. In 4
patients with basal thyrotropin values of 0.02 mU/1,
nuclide was only seen in the area of an adenoma in
the scan, although peripheral thyroid hormone levels
were in the normal ränge. In the other patients with
autonomous adenomas and basal thyrotropin values
in the ränge of 0.03 to 0.06 mU/1 (n = 7) nuclide
was seen not only in the adenoma, but also in the
paranodular thyroid tissue. We presume that the dif-
ference in thyrotropin secretion is responsible for the
paranodular nuclide uptake. Further clinical studies
are needed to clarify whether the application of thy-
roid hormones leads to a total suppression of thyro-
tropin and consequently to a decrease of paranodular
nuclide uptake.
We conclude that both assays provide results enabling
a clearcut discrimination of euthyroid controls and
of all non-responders to thyroliberin administration
(overt and borderline hyperthyroidism) using basal
thyrotropin levels alone. There was an overlap of
these two groups with patients showing a subnormal
increase upon Stimulation with thyroliberin. In
patients with autonomous adenomas the performance
of a thyroliberin Stimulation test provide additional
Information in the low ränge below 1.0 mU/1, i. e.
below the lower limit of detection of conventional
double antibody radioimmunoassays.
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